Natasha Penner

Company: Eisai

Job title: Senior Director & Head of Clinical Pharmacology

Seminars:

Panel Discussion: Is Plaque Reduction a Valid Marker of Response & Sufficiently Relevant to Drug Efficacy? 9:00 am

Navigating how the recent approval of amyloid clearing antibody drugs will affect regulator perception of plaque reduction as a marker of drug efficacy Reviewing if plaque targeting is relevant for drugs with a different mechanism of action and if this affects the safety profile too significantly Exploring the relevance of plaque clearance in heterogenous pathology…Read more

day: Conference Day One

Clinical Pharmacology Perspective on Anti-Amyloid Therapies for Alzheimer’s Disease 8:30 am

Amyloid hypothesis and antibodies against amyloid: mechanism matters Amyloid PET is correlated with clinical endpoints Amyloid reduction vs change in clinical endpoint CDR-SB in recent studies with anti-amyloid antibodies How anti-amyloid therapies are changing disease progression course in Alzheimer's DiseaseRead more

day: Conference Day One